Future of Multiple Sclerosis Drugs Market Hinges on FDA Approval and Research Activities

Multiple sclerosis is classified as a chronic, autoimmune, and inflammatory disease of the central nervous system, which affects the communication between different parts of the body and the brain. According to the National Multiple Sclerosis Society, over 1 million individuals have multiple sclerosis in the U.S. alone, and around 2.3 million people worldwide. These numbers continue to grow each year, which in turn makes it imperative to discover multiple sclerosis drugs with improved effectiveness and minimum side effects. Government and non-government entities in developed and developing regions are stepping up their efforts toward spreading awareness related to multiple sclerosis and are allocating substantial funds for research and development of new drugs.

Progress in life sciences and healthcare in the past decade, number of promising pipeline drug development projects, surge in the number of incidences of multiple sclerosis, and unmet needs pertaining to multiple sclerosis are some of the leading factors that are expected to accelerate the growth of the multiple sclerosis drugs market during the forecast period (2019-2027). Thus, the global multiple sclerosis drugs market, which was valued at US$ 20 Bn in 2019, is expected to reach US$ 31.5 Bn by 2027.

global multiple sclerosis drugs market infographic

To know the scope of our report Get a Sample on Point-of-Care Multiple Sclerosis Drugs Market   

Stakeholders Prioritize Development of New Drugs

Although prevalence of multiple sclerosis dates back to more than a hundred years, the first wave of drugs that exhibited moderate efficacy levels to treat multiple sclerosis gained approval 25 years ago. Since then, despite significant research, stakeholders were yet to find a treatment or a drug to cure multiple sclerosis.

In 2017, the Food and Drug Administration (FDA) gave the approval for Ocrevus ™ (ocrelizumab), a newly developed medication that has shown promising results in slowing down the progression of multiple sclerosis, and is also one of the first drugs to receive the approval for the treatment of primary-progressive multiple sclerosis. Clinical trials revealed that patients who were given doses of ocrelizumab exhibited fewer brain lesions and a significantly lower relapse rate. Furthermore, this drug showed greater efficacy in minimizing the annual relapse rate and a number of lesions that could be seen on MRI scans than interferon beta 1a (one of the most extensively used drugs to treat multiple sclerosis).

Get a glimpse of the in-depth analysis through our Report Brochure

At present, monoclonal antibodies and Interferon-β are some of the most popular drugs used in the treatment of multiple sclerosis. Monoclonal antibodies drug class segment are likely to retain the lead the multiple sclerosis drugs market during the forecast period and account for a market share of 40% by the end of 2027. 

New Multiple Sclerosis Medication in Research Pipeline Promises Better Results

Although there is no known cure for multiple sclerosis, the adoption of new medications to slow down the progression of multiple sclerosis and manage symptoms is on the rise. In the current scenario, research and development is playing a key role in the development of new treatments. Traditionally, disease-modifying therapies (DMTs) are the main type of medication used to treat multiple sclerosis. Players operating in the multiple sclerosis drugs market are focusing their efforts on gaining approval from the FDA for their newly developed drugs.

In recent times, the FDA has approved a range of disease-modifying therapies to treat different types of multiple sclerosis. Most recently, the FDA approved Fingolimod (Gilenya) to treat pediatric multiple sclerosis and glatiramer acetate injections (Glatopa). While new treatments and medications are receiving FDA approval, several other multiple sclerosis drugs are in the research pipeline and expected to enter the multiple sclerosis drugs market during the forecast period. For instance, a relatively recent phase III clinical trial revealed that siponimod, a potential multiple sclerosis drug, could reduce the relapse rate among individuals suffering from secondary progressive multiple sclerosis. Similarly, the findings from a recent phase II clinical trial suggested that ibudilast could potentially hamper the progression of disability in patients with multiple sclerosis.

Despite the onset of new oral medications, injectable multiple sclerosis drugs are expected to have a higher demand during the forecast period. Thus, in terms of route of administration, the parenteral segment of the multiple sclerosis drugs market is expected to reach a market value of US$ 12.7 Bn in 2020 and hold a market share of 63% in the same year.

global multiple sclerosis drugs market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

The global multiple sclerosis drugs market is expected to grow at a CAGR of 5.9% during the forecast period. The growth of the market can be primarily attributed to the significant rise in the number of research projects focusing on the discovery of new multiple sclerosis drugs with improved efficacy. Stakeholders should focus on gaining approval from the FDA for their newly developed multiple sclerosis drugs and simultaneously turn toward mergers and acquisitions to enhance their footprint in the current multiple sclerosis drugs market. Stakeholders should also focus on streamlining their distribution channels and explore opportunities within the e-Commerce sector.

Multiple Sclerosis Drugs Market: Overview

  • This report analyzes the current and future prospects of the global multiple sclerosis drugs market. Rise in prevalence and incidence of multiple sclerosis across the globe, rich product pipeline, and increase in awareness about multiple sclerosis are the key factors projected to drive the multiple sclerosis drugs market during the forecast period.
  • The report provides an elaborate executive summary, which comprises a snapshot of the various segments of the global multiple sclerosis drugs market. The report also provides information and data analysis of the multiple sclerosis drugs market with regards to segments based on drug class, disease type, route of administration, distribution channel, and region.
  • The overview section of the report provides detailed qualitative analysis of drivers and restraints impacting the multiple sclerosis drugs market along with opportunities in the global market
  • Additionally, the multiple sclerosis drugs market report includes company profiles and competitive matrix, which provide data about their business, product portfolio, and competitive landscape in the global multiple sclerosis drugs market
  • The report includes data analysis on the multiple sclerosis drugs market attractiveness by region and segments
  • The last section of the report provides quantitative and qualitative analysis on market share of key players operating in the multiple sclerosis drugs market. It elaborates the key competitive strategies adopted by the major industry players, thereby presenting a thorough understanding of the competitive scenario in the global multiple sclerosis drugs market. 

Multiple Sclerosis Drugs Market: Key Segments

  • In terms of drug class, the multiple sclerosis drugs market has been classified into interferon beta, sphingosine 1 phosphate receptor modulators, mixed polymers, NF-κB inhibitor, pyrimidine synthesis inhibitor, monoclonal antibodies, corticosteroids, adrenocorticotropic hormone, and others. The interferon beta segment held a major share of the multiple sclerosis drugs market in 2018. However, the monoclonal antibodies segment is anticipated to dominate the multiple sclerosis drugs market during the forecast period.
  • In terms of disease type, the multiple sclerosis drugs market has been classified into relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS (PRMS). The relapsing-remitting MS (RRMS) segment is expected to dominate the multiple sclerosis drugs market during the forecast period.
  • Based on route of administration, the multiple sclerosis drugs market has been bifurcated into parenteral and oral. The parenteral segment is likely to expand at a higher CAGR during the forecast period, due to large patient pool with RRMS. About 75% to 85% of the population suffering from MS have RRMS.
  • In terms of distribution channel, the multiple sclerosis drugs market has been categorized into hospital pharmacies, retail pharmacies & drug stores, and online pharmacies. The retail pharmacies & drug stores segment is projected to dominate the multiple sclerosis drugs market during the forecast period.
  • The market size and forecast for each of these segments have been provided from 2017 to 2027. The CAGR of respective segment has also been provided for the forecast period from 2019 to 2027, considering 2018 as the base year. 

Multiple Sclerosis Drugs Market: Regional Outlook

  • In terms of region, the multiple sclerosis drugs market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa)
  • The report provides market size and forecast for each region and countries/sub-regions from 2017 to 2027. Compound annual growth rates (CAGRs) of each of these regions and countries have also been provided for the forecast period from 2019 to 2027, considering 2018 as the base year. The multiple sclerosis drugs market study also covers the competitive scenario in these regions. 

Companies Mentioned in Report

  • Key players in the multiple sclerosis drugs market have been profiled based on key aspects such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
  • Major companies profiled in the multiple sclerosis drugs market report are
    • Bayer AG
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Sanofi
    • F. Hoffmann-La Roche Ltd.
    • Celgene Corporation
    • Acorda Therapeutics, Inc.
    • Biogen, Inc.
    • Actelion Pharmaceuticals (Johnson & Johnson)
    • EMD Serono (Merck KGaA)
    • AbbVie, Inc.

Multiple Sclerosis Drugs Market – Segmentation

Drug Class

Interferon Beta

Sphingosine 1 Phosphate Receptor Modulators

Mixed Polymers

NF-κB Inhibitor

Pyrimidine Synthesis Inhibitor

Monoclonal Antibodies

Corticosteroids

Adrenocorticotropic Hormone

Others

Disease Type

Relapsing-remitting MS (RRMS)

Primary-progressive MS (PPMS)

Secondary-progressive MS (SPMS)

Progressive-relapsing MS (PRMS)

Route of Administration

Parenteral

Oral

Distribution Channel

Hospital Pharmacies

Retail Pharmacies & Drug Stores

Online Pharmacies

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

Multiple sclerosis drugs market is expected to reach US$ 31.5 Bn by 2027

Multiple sclerosis drugs market is projected to expand at a CAGR of 5.9% during 2017 - 2027

Multiple sclerosis drugs market is driven by rise in prevalence and incidence of multiple sclerosis across the globe

North America accounted for a major share of the global multiple sclerosis drugs market

Key players in the multiple sclerosis drugs market report include Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Multiple Sclerosis Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Multiple Sclerosis Drugs Market Introduction

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Regulatory Scenario

    5.3. Disease Epidemiology

    5.4. Market Access Overview

    5.5. Key Mergers & Acquisitions 

6. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Drug Class 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2027

        6.3.1. Interferon Beta

        6.3.2. Sphingosine 1 Phosphate Receptor Modulators

        6.3.3. Mixed Polymers

        6.3.4. NF-κB Inhibitor

        6.3.5. Pyrimidine Synthesis Inhibitor

        6.3.6. Monoclonal Antibodies

        6.3.7. Corticosteroids

        6.3.8. Adrenocorticotropic Hormone

        6.3.9. Others

    6.4. Market Attractiveness, by Drug Class 

7. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Disease Type 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Disease Type, 2017–2027

        7.3.1. Relapsing-remitting MS (RRMS)

        7.3.2. Primary-progressive MS (PPMS)

        7.3.3. Secondary-progressive MS (SPMS)

        7.3.4. Progressive-relapsing MS (PRMS)

    7.4. Market Attractiveness, by Disease Type 

8. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Route of Administration 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Route of Administration, 2017–2027

        8.3.1. Parenteral

        8.3.2. Oral

    8.4. Market Attractiveness by Route of Administration 

9. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Distribution Channel 

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Distribution Channel, 2017–2027

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies & Drug Stores

        9.3.3. Online Pharmacies

    9.4. Market Attractiveness, by Distribution Channel 

10. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America 

        10.2.2. Europe 

        10.2.3. Asia Pacific 

        10.2.4. Latin America 

        10.2.5. Middle East & Africa 

    10.3. Market Attractiveness, by Country/Region

11. North America Multiple Sclerosis Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2027

        11.2.1. Interferon Beta

        11.2.2. Sphingosine 1 Phosphate Receptor Modulators

        11.2.3. Mixed Polymers

        11.2.4. NF-κB Inhibitor

        11.2.5. Pyrimidine Synthesis Inhibitor

        11.2.6. Monoclonal Antibodies

        11.2.7. Corticosteroids

        11.2.8. Adrenocorticotropic Hormone

        11.2.9. Others

    11.3. Market Value Forecast, by Disease Type, 2017–2027

        11.3.1. Relapsing-remitting MS (RRMS)

        11.3.2. Primary-progressive MS (PPMS)

        11.3.3. Secondary-progressive MS (SPMS)

        11.3.4. Progressive-relapsing MS (PRMS)

    11.4. Market Value Forecast, by Route of Administration, 2017–2027

        11.4.1. Parenteral

        11.4.2. Oral

    11.5. Market Value Forecast, by Distribution Channel, 2017–2027

        11.5.1. Hospital Pharmacies

        11.5.2. Retail Pharmacies & Drug Stores

        11.5.3. Online Pharmacies

    11.6. Market Value Forecast, by Country, 2017–2027

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis 

        11.7.1. By Drug Class 

        11.7.2. By Disease Type 

        11.7.3. By Route of Administration 

        11.7.4. By Distribution Channel 

        11.7.5. By Country

12. Europe Multiple Sclerosis Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2027

        12.2.1. Interferon Beta

        12.2.2. Sphingosine 1 Phosphate Receptor Modulators

        12.2.3. Mixed Polymers

        12.2.4. NF-κB Inhibitor

        12.2.5. Pyrimidine Synthesis Inhibitor

        12.2.6. Monoclonal Antibodies

        12.2.7. Corticosteroids

        12.2.8. Adrenocorticotropic Hormone

        12.2.9. Others

    12.3. Market Value Forecast, by Disease Type, 2017–2027

        12.3.1. Relapsing-remitting MS (RRMS)

        12.3.2. Primary-progressive MS (PPMS)

        12.3.3. Secondary-progressive MS (SPMS)

        12.3.4. Progressive-relapsing MS (PRMS)

    12.4. Market Value Forecast, by Route of Administration, 2017–2027

        12.4.1. Parenteral

        12.4.2. Oral

    12.5. Market Value Forecast, by Distribution Channel, 2017–2027

        12.5.1. Hospital Pharmacies

        12.5.2. Retail Pharmacies & Drug Stores

        12.5.3. Online Pharmacies

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2027

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Italy

        12.6.5. Spain

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis 

        12.7.1. By Drug Class 

        12.7.2. By Disease Type 

        12.7.3. By Route of Administration 

        12.7.4. By Distribution Channel 

        12.7.5. By Country/Sub-region

13. Asia Pacific Multiple Sclerosis Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Class, 2017–2027

        13.2.1. Interferon Beta

        13.2.2. Sphingosine 1 Phosphate Receptor Modulators

        13.2.3. Mixed Polymers

        13.2.4. NF-κB Inhibitor

        13.2.5. Pyrimidine Synthesis Inhibitor

        13.2.6. Monoclonal Antibodies

        13.2.7. Corticosteroids

        13.2.8. Adrenocorticotropic Hormone

        13.2.9. Others

    13.3. Market Value Forecast, by Disease Type, 2017–2027

        13.3.1. Relapsing-remitting MS (RRMS)

        13.3.2. Primary-progressive MS (PPMS)

        13.3.3. Secondary-progressive MS (SPMS)

        13.3.4. Progressive-relapsing MS (PRMS)

    13.4. Market Value Forecast, by Route of Administration, 2017–2027

        13.4.1. Parenteral

        13.4.2. Oral

    13.5. Market Value Forecast, by Distribution Channel, 2017–2027

        13.5.1. Hospital Pharmacies

        13.5.2. Retail Pharmacies & Drug Stores

        13.5.3. Online Pharmacies

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2027

        13.6.1. China

        13.6.2. India

        13.6.3. Japan

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis 

        13.7.1. By Drug Class 

        13.7.2. By Disease Type 

        13.7.3. By Route of Administration 

        13.7.4. By Distribution Channel 

        13.7.5. By Country/Sub-region

14. Latin America Multiple Sclerosis Drugs Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Class, 2017–2027

        14.2.1. Interferon Beta

        14.2.2. Sphingosine 1 Phosphate Receptor Modulators

        14.2.3. Mixed Polymers

        14.2.4. NF-κB Inhibitor

        14.2.5. Pyrimidine Synthesis Inhibitor

        14.2.6. Monoclonal Antibodies

        14.2.7. Corticosteroids

        14.2.8. Adrenocorticotropic Hormone

        14.2.9. Others

    14.3. Market Value Forecast, by Disease Type, 2017–2027

        14.3.1. Relapsing-remitting MS (RRMS)

        14.3.2. Primary-progressive MS (PPMS)

        14.3.3. Secondary-progressive MS (SPMS)

        14.3.4. Progressive-relapsing MS (PRMS)

    14.4. Market Value Forecast, by Route of Administration, 2017–2027

        14.4.1. Parenteral

        14.4.2. Oral

    14.5. Market Value Forecast, by Distribution Channel, 2017–2027

        14.5.1. Hospital Pharmacies

        14.5.2. Retail Pharmacies & Drug Stores

        14.5.3. Online Pharmacies

    14.6. Market Value Forecast, by Country/Sub-region, 2017–2027

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis 

        14.7.1. By Drug Class 

        14.7.2. By Disease Type 

        14.7.3. By Route of Administration 

        14.7.4. By Distribution Channel 

        14.7.5. By Country/Sub-region

15. Middle East & Africa Multiple Sclerosis Drugs Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Drug Class, 2017–2027

        15.2.1. Interferon Beta

        15.2.2. Sphingosine 1 Phosphate Receptor Modulators

        15.2.3. Mixed Polymers

        15.2.4. NF-κB Inhibitor

        15.2.5. Pyrimidine Synthesis Inhibitor

        15.2.6. Monoclonal Antibodies

        15.2.7. Corticosteroids

        15.2.8. Adrenocorticotropic Hormone

        15.2.9. Others

    15.3. Market Value Forecast, by Disease Type, 2017–2027

        15.3.1. Relapsing-remitting MS (RRMS)

        15.3.2. Primary-progressive MS (PPMS)

        15.3.3. Secondary-progressive MS (SPMS)

        15.3.4. Progressive-relapsing MS (PRMS)

    15.4. Market Value Forecast, by Route of Administration, 2017–2027

        15.4.1. Parenteral

        15.4.2. Oral

    15.5. Market Value Forecast, by Distribution Channel, 2017–2027

        15.5.1. Hospital Pharmacies

        15.5.2. Retail Pharmacies & Drug Stores

        15.5.3. Online Pharmacies

    15.6. Market Value Forecast, by Country/Sub-region, 2017–2027

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis 

        15.7.1. By Drug Class 

        15.7.2. By Disease Type 

        15.7.3. By Route of Administration 

        15.7.4. By Distribution Channel 

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Share Analysis, by Company, 2018

    16.2. Company Profiles

        16.2.1. Bayer AG

            16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.1.2. Financial Overview

            16.2.1.3. Product Portfolio

            16.2.1.4. SWOT Analysis 

            16.2.1.5. Strategic 

        16.2.2. Teva Pharmaceutical Industries Ltd.

            16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.2.2. Financial Overview

            16.2.2.3. Product Portfolio

            16.2.2.4. SWOT Analysis 

            16.2.2.5. Strategic 

        16.2.3. Novartis AG

            16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.3.2. Financial Overview

            16.2.3.3. Product Portfolio

            16.2.3.4. SWOT Analysis 

            16.2.3.5. Strategic 

        16.2.4. Sanofi

            16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.4.2. Financial Overview

            16.2.4.3. Product Portfolio

            16.2.4.4. SWOT Analysis 

            16.2.4.5. Strategic 

        16.2.5. F. Hoffmann-La Roche Ltd.

            16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.5.2. Financial Overview

            16.2.5.3. Product Portfolio

            16.2.5.4. SWOT Analysis 

            16.2.5.5. Strategic 

        16.2.6. Celgene Corporation

            16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.6.2. Financial Overview

            16.2.6.3. Product Portfolio

            16.2.6.4. SWOT Analysis 

            16.2.6.5. Strategic 

        16.2.7. Acorda Therapeutics, Inc.

            16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.7.2. Financial Overview

            16.2.7.3. Product Portfolio

            16.2.7.4. SWOT Analysis 

            16.2.7.5. Strategic 

        16.2.8. Biogen, Inc.

            16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.8.2. Financial Overview

            16.2.8.3. Product Portfolio

            16.2.8.4. SWOT Analysis 

            16.2.8.5. Strategic 

        16.2.9. Actelion Pharmaceuticals (Johnson & Johnson)

            16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.9.2. Financial Overview

            16.2.9.3. Product Portfolio

            16.2.9.4. SWOT Analysis 

            16.2.9.5. Strategic 

        16.2.10. EMD Serono (Merck KGaA)

            16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.10.2. Financial Overview

            16.2.10.3. Product Portfolio

            16.2.10.4. SWOT Analysis 

            16.2.10.5. Strategic 

        16.2.11. AbbVie, Inc.

            16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.11.2. Financial Overview

            16.2.11.3. Product Portfolio

            16.2.11.4. SWOT Analysis 

            16.2.11.5. Strategic 

List of Tables

Table 01: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 02: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 03: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 04: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 05: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 06: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 07: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 08: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 09: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 10: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 11: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 12: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 13: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 14: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 15: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 16: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 17: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 18: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 19: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 20: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 21: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 22: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 23: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 24: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 25: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 26: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 27: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 28: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 29: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 30: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

List of Figures

Figure 01: Global Multiple Sclerosis Drugs Market Snapshot

Figure 02: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, 2017–2027

Figure 03: Global Multiple Sclerosis Drugs Market Value Share, by Drug Class, 2018

Figure 04: Global Multiple Sclerosis Drugs Market Value Share, by Disease Type, 2018

Figure 05: Global Multiple Sclerosis Drugs Market Value Share, by Route of Administration, 2018

Figure 06: Global Multiple Sclerosis Drugs Market Value Share, by Distribution Channel, 2018

Figure 07: Global Multiple Sclerosis Drugs Market Value Share, by Region, 2018

Figure 08: Regulatory Approval Process - U.S.

Figure 09: Regulatory Approval Process - Europe

Figure 10: Regulatory Approval Process - Japan

Figure 11: Regulatory Approval Process - China

Figure 12: Global Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 13: Global Multiple Sclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 14: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Interferon Beta, 2017–2027

Figure 15: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Sphingosine 1 Phosphate Receptor Modulators, 2017–2027

Figure 16: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Mixed Polymers, 2017–2027

Figure 17: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by NF-κB Inhibitors, 2017–2027

Figure 18: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Pyrimidine Synthesis Inhibitors, 2017–2027

Figure 19: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Monoclonal Antibodies, 2017–2027

Figure 20: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Corticosteroids, 2017–2027

Figure 21: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Adrenocorticotropic Hormone, 2017–2027

Figure 22: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2017–2027

Figure 23: Global Multiple Sclerosis Drugs Market Value Share Analysis, by Disease Type, 2018 and 2027

Figure 24: Global Multiple Sclerosis Drugs Market Attractiveness Analysis, by Disease Type, 2019–2027

Figure 25: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Relapsing-remitting MS (RRMS), 2017–2027

Figure 26: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Primary-progressive MS (PPMS), 2017–2027

Figure 27: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Secondary-progressive MS (SPMS), 2017–2027

Figure 28: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Progressive-relapsing MS (PRMS), 2017–2027

Figure 29: Global Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 30: Global Multiple Sclerosis Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 31: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Parenteral, 2017–2027

Figure 32: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Oral, 2017–2027

Figure 33: Global Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 34: Global Multiple Sclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 35: Global Multiple Sclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

Figure 36: Global Multiple Sclerosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies & Drug Stores, 2017–2027

Figure 37: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027

Figure 38: Global Multiple Sclerosis Drugs Market Value Share, by Region, 2018 and 2027

Figure 39: Global Multiple Sclerosis Drugs Market Attractiveness, by Region, 2019–2027

Figure 40: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 41: North America Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Country, 2018 & 2027

Figure 42: North America Multiple Sclerosis Drugs Market Attractiveness Analysis, by Country, 2019?2027

Figure 43: North America Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Drug Class, 2018 & 2027

Figure 44: North America Multiple Sclerosis Drugs Market Attractiveness, by Drug Class, 2019?2027

Figure 45: North America Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Disease Type, 2018 & 2027

Figure 46: North America Multiple Sclerosis Drugs Market Attractiveness, by Disease Type, 2019?2027

Figure 47: North America Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Route of Administration, 2018 & 2027

Figure 48: North America Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Distribution Channel, 2018 & 2027

Figure 49: North America Multiple Sclerosis Drugs Market Attractiveness, by Route of Administration, 2019?2027

Figure 50: North America Multiple Sclerosis Drugs Market Attractiveness, by Distribution Channel, 2019?2027

Figure 51: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 52: Europe Multiple Sclerosis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 53: Europe Multiple Sclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019?2027

Figure 54: Europe Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 55: Europe Multiple Sclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019?2027

Figure 56: Europe Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Disease Type, 2018 & 2027

Figure 57: Europe Multiple Sclerosis Drugs Market Attractiveness, by Disease Type, 2019?2027

Figure 58: Europe Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 59: Europe Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 60: Europe Multiple Sclerosis Drugs Market Attractiveness Analysis, by Route of Administration, 2019?2027

Figure 61: Europe Multiple Sclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019?2027

Figure 62: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 63: Asia Pacific Multiple Sclerosis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 64: Asia Pacific Multiple Sclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 65: Asia Pacific Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 66: Asia Pacific Multiple Sclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 67: Asia Pacific Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Disease Type, 2018 & 2027

Figure 68: Asia Pacific Multiple Sclerosis Drugs Market Attractiveness, by Disease Type, 2019?2027

Figure 69: Asia Pacific Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 70: Asia Pacific Multiple Sclerosis Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 71: Asia Pacific Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 72: Asia Pacific Multiple Sclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 73: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 74: Latin America Multiple Sclerosis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 75: Latin America Multiple Sclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 76: Latin America Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 77: Latin America Multiple Sclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 78: Latin America Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Disease Type, 2018 and 2027

Figure 79: Latin America Multiple Sclerosis Drugs Market Attractiveness, by Disease Type, 2019?2027

Figure 80: Latin America Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 81: Latin America Multiple Sclerosis Drugs Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 82: Latin America Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 83: Latin America Multiple Sclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 84: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 85: Middle East & Africa Multiple Sclerosis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 86: Middle East & Africa Multiple Sclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027

Figure 87: Middle East & Africa Multiple Sclerosis Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 88: Middle East & Africa Multiple Sclerosis Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027

Figure 89: Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%) Analysis, by Disease Type, 2018 & 2027

Figure 90: Middle East & Africa Multiple Sclerosis Drugs Market Attractiveness, by Disease Type, 2019?2027

Figure 91: Middle East & Africa Multiple Sclerosis Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 92: Middle East & Africa Multiple Sclerosis Drugs Market Attractiveness Analysis, by Route of Administration, 2019-2027

Figure 93: Middle East & Africa Multiple Sclerosis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 94: Middle East & Africa Multiple Sclerosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Multiple Sclerosis Drugs Market